Chui Ming Gemmy Cheung

Dr. Chui Ming Gemmy Cheung

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in The Lancet Global Health
Verified
Journal Article
Open access
WWWan Ling Wong
Wan Ling Wong
XSXinyi Su
Xinyi Su
XLXiang Li
Xiang Li
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
RKRonald Klein
Ronald Klein
TWTien Yin Wong
Tien Yin Wong
Numerous population-based studies of age-related macular degeneration have been reported around the world, with the results of some studies suggesting racial or ethnic differences in disease prevalence. Integrating these resources to provide summarised data to establish worldwide prevalence and to project the number of people with age-related macular degeneration from 2020 to 2040 would be a useful guide for global strategies. We did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013. Only studies using retinal photographs and standardised grading classifications (the Wisconsin age-related maculopathy grading system, the international classification for age-related macular degeneration, or the Rotterdam staging system) were included. Hierarchical Bayesian approaches were used to estimate the pooled prevalence, the 95% credible intervals (CrI), and to examine the difference in prevalence by ethnicity (European, African, Hispanic, Asian) and region (Africa, Asia, Europe, Latin America and the Caribbean, North America, and Oceania). UN World Population Prospects were used to project the number of people affected in 2014 and 2040. Bayes factor was calculated as a measure of statistical evidence, with a score above three indicating substantial evidence. Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively. We found a higher prevalence of early and any age-related macular degeneration in Europeans than in Asians (early: 11.2% vs 6.8%, Bayes factor 3.9; any: 12.3% vs 7.4%, Bayes factor 4.3), and early, late, and any age-related macular degeneration to be more prevalent in Europeans than in Africans (early: 11.2% vs 7.1%, Bayes factor 12.2; late: 0.5% vs 0.3%, 3.7; any: 12.3% vs 7.5%, 31.3). There was no difference in prevalence between Asians and Africans (all Bayes factors <1). Europeans had a higher prevalence of geographic atrophy subtype (1.11%, 95% CrI 0.53-2.08) than Africans (0.14%, 0.04-0.45), Asians (0.21%, 0.04-0.87), and Hispanics (0.16%, 0.05-0.46). Between geographical regions, cases of early and any age-related macular degeneration were less prevalent in Asia than in Europe and North America (early: 6.3% vs 14.3% and 12.8% [Bayes factor 2.3 and 7.6]; any: 6.9% vs 18.3% and 14.3% [3.0 and 3.8]). No significant gender effect was noted in prevalence (Bayes factor <1.0). The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399). These estimates indicate the substantial global burden of age-related macular degeneration. Summarised data provide information for understanding the effect of the condition and provide data towards designing eye-care strategies and health services around the world. National Medical Research Council, Singapore.

12 December 2017 in JAMA
Verified
Journal Article
Open access
PDF file
DTDaniel Shu Wei Ting
Daniel Shu Wei Ting
CCCarol Yim-Lui Cheung
Carol Yim-Lui Cheung
GLGilbert Lim
Gilbert Lim
GTGavin Siew Wei Tan
Gavin Siew Wei Tan
NQNguyen D. Quang
Nguyen D. Quang
TWTien Yin Wong
Tien Yin Wong
By 2040, it is projected that approximately 600 million people will have diabetes, with one-third expected to have diabetic retinopathy.1-3 Screening for diabetic retinopathy, coupled with timely referral and treatment, is a universally accepted strategy for blindness prevention.2 However, programs for screening diabetic retinopathy are challenged by issues related to implementation, availability of human assessors, and long-term financial sustainability.2,4-7

17 March 2016 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
TWTien Y. Wong
Tien Y. Wong
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
MLMichael Larsen
Michael Larsen
SSSanjay Sharma
Sanjay Sharma
Rafael SimóRafael Simó
Rafael Simó

17 February 2016 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
DTDaniel Shu Wei Ting
Daniel Shu Wei Ting
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
TWTien Yin Wong
Tien Yin Wong

1 May 2015 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
KOKyoko Ohno-Matsui
Kyoko Ohno-Matsui
RKRyo Kawasaki
Ryo Kawasaki
JJJost B. Jonas
Jost B. Jonas
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
SSSeang-Mei Saw
Seang-Mei Saw
BFBrian Fleck
Brian Fleck

12 February 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RARupesh Agrawal
Rupesh Agrawal
PGPreeti Gupta
Preeti Gupta
KTKara-Anne Tan
Kara-Anne Tan
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
TWTien-Yin Wong
Tien-Yin Wong
CCChing-Yu Cheng
Ching-Yu Cheng
The vascularity of the choroid has been implicated in the pathogenesis of various eye diseases. To date, no established quantifiable parameters to estimate vascular status of the choroid exists. Choroidal vascularity index (CVI) may potentially be used to assess vascular status of the choroid. We aimed to establish normative database for CVI and identify factors associated with CVI in healthy eyes. In this population-based study on 345 healthy eyes, choroidal enhanced depth imaging optical coherence tomography scans were segmented by modified image binarization technique. Total subfoveal choroidal area (TCA) was segmented into luminal (LA) and stromal (SA) area. CVI was calculated as the proportion of LA to TCA. Linear regression was used to identify ocular and systemic factors associated with CVI and subfoveal choroidal thickness (SFCT). Subfoveal CVI ranged from 60.07 to 71.27% with a mean value of 65.61 ± 2.33%. CVI was less variable than SFCT (coefficient of variation for CVI was 3.55 vs 40.30 for SFCT). Higher CVI was associated with thicker SFCT, but not associated with most physiological variables. CVI was elucidated as a significant determinant of SFCT. While SFCT was affected by many factors, CVI remained unaffected suggesting CVI to be a more robust marker of choroidal diseases.